Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-H0731 + SOC in virally-suppressed cHBV
NCT03576066Phase 2Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ABI-H0731 + SOC NUC with Placebo + SOC NUC (2 arms). Primary endpoints: Change in Mean log10 Serum HBsAg at 24 weeks and Change in Mean log10 Serum HBeAg at 24 weeks. Started Jun 2018; status: completed.
02
Drugs
vebicorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03576066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576066.